v3.23.2
Revenue Recognition - Additional Information (Detail) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Apr. 30, 2022
Mar. 31, 2022
Jan. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Collaboration Arrangement [Line Items]                
Accounts receivable, net - related party       $ 10,124   $ 10,124   $ 3,260
Total revenue       6,933 $ 23,003 13,098 $ 27,793  
Commercial supply revenue                
Collaboration Arrangement [Line Items]                
Total revenue       1,400   4,591 4,790  
License and milestone fees                
Collaboration Arrangement [Line Items]                
Total revenue         15,000   15,000  
Royalty revenue                
Collaboration Arrangement [Line Items]                
Total revenue       123   248    
Collaborative revenue                
Collaboration Arrangement [Line Items]                
Total revenue       5,410 8,003 8,160 8,003  
Clinical compound revenue                
Collaboration Arrangement [Line Items]                
Total revenue           99    
CSL Vifor Profit Sharing [Member] | Collaborative revenue                
Collaboration Arrangement [Line Items]                
Total revenue       5,410 8,003 8,160 8,003  
CSL Vifor, Maruishi and CKDP Agreements [Member]                
Collaboration Arrangement [Line Items]                
Other contract Assets       0   0   0
Other contract liabilities       0   0   0
Maruishi Pharmaceutical Co., Ltd. [Member] | Clinical compound revenue                
Collaboration Arrangement [Line Items]                
Total revenue       0 0 99 0  
CSL Vifor [Member]                
Collaboration Arrangement [Line Items]                
Accounts receivable, net - related party       10,124   10,124   $ 3,260
CSL Vifor [Member] | Commercial supply revenue                
Collaboration Arrangement [Line Items]                
Total revenue       1,400   4,591 4,790  
CSL Vifor [Member] | Commercial Supply Revenue With No Associated Costs Of Goods Sold [Member]                
Collaboration Arrangement [Line Items]                
Total revenue     $ 2,295   0      
Cost of goods sold     $ 0          
CSL Vifor [Member] | Commercial Supply Revenue With Associated Costs Of Goods Sold [Member]                
Collaboration Arrangement [Line Items]                
Revenue   $ 2,495            
Cost of goods sold   $ 2,081   1,418   4,008    
CSL Vifor [Member] | Royalty revenue                
Collaboration Arrangement [Line Items]                
Total revenue         $ 0   $ 0  
CSL Vifor [Member] | Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 [Member] | License and milestone fees | Regulatory Milestones [Member]                
Collaboration Arrangement [Line Items]                
Proceeds from milestone payments $ 15,000              
CSL Vifor [Member] | CSL Vifor Kapruvia [Member] | Royalty revenue                
Collaboration Arrangement [Line Items]                
Total revenue       $ 123   $ 248